A Phase 3, Multi-center, Open-label Extension Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)
Latest Information Update: 20 May 2024
At a glance
- Drugs Viltolarsen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Acronyms RACER-53X; RACER53-X
- Sponsors NS Pharma
- 13 Feb 2024 Planned End Date changed from 1 Jun 2026 to 1 Nov 2025.
- 13 Feb 2024 Planned primary completion date changed from 1 Jun 2026 to 1 Oct 2025.
- 13 Feb 2024 Status changed from recruiting to active, no longer recruiting.